OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	92
Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings	63
Long-acting preexposure prophylaxis: early data on roll-out in the United States	40
Humoral immunity in HIV-1 post-treatment controllers	38
Future options for long-acting HIV treatment and prevention	28
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	26
Assessing proviral competence: current approaches to evaluate HIV-1 persistence	26
Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV	25
Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine	24
Technologies for HIV-1 drug resistance testing: inventory and needs	22
Bridging the gaps in perinatal HIV: treatment and prevention	21
Preventing perinatal HIV acquisition; current gaps and future perspectives	19
Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children	19
Cardiovascular health in people with perinatally acquired HIV – where do we stand?	19
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	18
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	17
Editorial introductions	17
Elite controllers microbiome: unraveling the mystery of association and causation	17
Editorial introductions	17
Humanized mice for studying HIV latency and potentially its eradication	16
Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV	16
HIV cure: an acceptability scientific agenda	16
Host factors predisposing to kidney disease in people with HIV	14
Editorial: New drugs for HIV: quo vadis?	14
Editorial: Immune-mediated control of HIV	14

Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	14
Is an HIV vaccine still achievable?	13
The severity of COVID-19 across the spectrum of HIV	13
Pediatric perspective: the microbiome in vertical HIV-infection: unravelling gaps, challenges, and therapeutic potential	12
HIV and cardiovascular disease: the role of inflammation	11
Exosomes in HIV infection	11
The sounds of silencing: dynamic epigenetic control of HIV latency	11
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy	11
The changing use and program costs of HIV-related laboratory testing over 20 years in an HIV cohort	10
Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation	10
Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection	10
Lenacapavir: a first-in-class HIV-1 capsid inhibitor	10
HIV drug resistance in various body compartments	10
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	10
Delivery platforms for broadly neutralizing antibodies	9
Strategies to target the central nervous system HIV reservoir	8
“Block and lock” viral integration sites in persons with drug-free control of HIV-1 infection	8
An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors	8
Editorial introduction	8
Harnessing natural killer cells to target HIV-1 persistence	8
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	7
Editorial introduction	7
What's in a cure: designing a broad-spectrum HIV gene therapy	7
Editorial introduction	7
Editorial introductions	6
Polyfunctionality of broadly neutralizing HIV-1 antibodies	6
Editorial introductions	6
Anticipating HIV viral escape – resistance to active and passive immunization	5
Causes and outcomes of hepatic fibrosis in persons living with HIV	5
Intersections between HIV and obesity in emerging economies	5
Soluble markers of viral rebound and post-treatment HIV control	5
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	5
Emerging role of natural killer cells in non-AIDS comorbidities during suppressive antiretroviral therapy	5
Update on treatment as prevention of HIV illness, death, and transmission: sub-Saharan Africa HIV financing and progress towards the 95–95–95 target	5
Advances in the mathematical modeling of posttreatment control of HIV-1	5
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’	5
The rectal microbiome: understanding its role in HIV transmission	5
Editorial introduction	5
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection	5
Long-acting antiretroviral therapy in the context of viral suppression	5
Context, COVID-19 and comorbidities: exploring emergent directions in syndemics and HIV research	4
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	4
Persistent HIV-1 transcription during ART: time to reassess its significance?	4
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	4
The utility of nonhuman primate models for understanding acute HIV-1 infection	4
Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV	4
Acute retroviral syndrome	4
Engineering strategies of Anti-HIV antibody therapeutics in clinical development	3
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	3
Harnessing immune cells to eliminate HIV reservoirs	3

Pharmacological approaches to promote cell death of latent HIV reservoirs	3
New latency-promoting agents for a block-and-lock functional cure strategy	3
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	3
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	3
Targeting noncoding RNAs to reactivate or eliminate latent HIV reservoirs	3
A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117	3
HIV-1 subtypes and latent reservoirs	3
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	3
The intertwined epidemics of HIV and COVID-19 – emerging data and responses	3
Deciphering HIV-associated inflammation: microbiome's influence and experimental insights	3
HIV persistence in lymph nodes	3
Targeting enhanced neutralizing antibody responses via increased germinal center activity: early-phase vaccine trials with novel clinical designs	3
Moving toward equity: fostering transdisciplinary research between the social and behavioral sciences and implementation science to end the HIV epidemic	3
Editorial introduction	3
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	3
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	3
Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV	2
Monocytes across life span in HIV infection: lights and shadows	2
Effective innate immune response in natural HIV-1 controllers. Can mimicking lead to novel preventive and cure strategies against HIV-1?	2
Editorial introductions	2
Editorial introduction	2
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	2
Editorial introduction	2
Editorial introduction	2
Editorial introductions	2
Public health implications of diagnosing and treating acute HIV	2
The pathogenesis of obesity in people living with HIV	2
Frailty: the current challenge for aging people with HIV	2
Clinical consequences of weight gain during treatment for HIV infection	2
Editorial introduction	2
Editorial: Is it time to implement injectable antiretroviral treatments globally?	2
Editorial introductions	2
HIV-1 reservoir landscape of post-treatment control	1
Defining multimorbidity in people with HIV – what matters most?	1
Untangling the role of the microbiome across the stages of HIV disease	1
HIV and co-morbidities – an evolving, global view	1
Antibody interventions in HIV: broadly neutralizing mAbs in children	1
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	1
Neuropathogenesis of acute HIV: mechanisms, biomarkers, and therapeutic approaches	1
Long-acting ART and preexposure prophylaxis: profound promise but stunted access	1
Long COVID in people living with HIV	1
HIV T-cell immunogen design and delivery	1
Children who are HIV exposed-uninfected: does maternal ART regimen matter?	1
Editorial introduction	1
Cardiovascular toxicity of contemporary antiretroviral therapy	1
Visualization of HIV-1 reservoir: an imaging perspective	1
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	1
The vaginal microbiome and HIV transmission dynamics	1
Challenges towards an AIDS-free generation in Africa and Asia	1
Loneliness and social isolation in people with HIV	1
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV	1
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	1
Current co-morbidities burden in patients living with HIV in low- and middle-income countries	1
Considerations for successful therapeutic immunization in HIV cure	1
Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages	1
Accelerating HIV vaccine development through meaningful engagement of local scientists and communities	1
HIV-1 transcriptional modulation: novel host factors and prospective therapeutic strategies	1
Implementation of long-acting antiretroviral therapy in low-income and middle-income countries	1
Persistent elite controllers as the key model to identify permanent HIV remission	1
Zika virus: an overview update	1
Pediatric immunotherapy and HIV control	1
Paediatric antiretroviral therapy challenges with emerging integrase resistance	1
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	1